“An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract (hereinafter Study)” Durvalumab (hereinafter Study Drug)”

Type of Cancer
Gynecologic

Phase

Division (Location)

Study ID

NCT#

Brief Description
“An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract (hereinafter Study)” Durvalumab (hereinafter Study Drug)”

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.